Publications by authors named "F Piccotti"
Article Synopsis
- Anthracyclines, notably doxorubicin (DOX), remain essential for breast cancer treatment despite the rise of targeted therapies, primarily due to their effectiveness in disrupting DNA replication in cancer cells.
- However, DOX's non-specific action leads to severe side effects, necessitating an understanding of its impact on immune cells, particularly T cells, to preserve anti-tumor immunity during treatment.
- The investigation revealed that a novel DOX formulation using ferritin nanocages (FerOX) can target tumors more effectively while minimizing the drug's cytotoxic effects on T cells, enhancing both anti-tumor efficacy and immune protection.
Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.
Ther Adv Med Oncol
September 2023
Background: Systemic inflammatory markers draw great interest as potential blood-based prognostic factors in several oncological settings.
Objectives: The aim of this study is to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and pan-immune-inflammation value (PIV) predict nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in node-positive (cN+) breast cancer (BC) patients.
Design: Clinically, cN+ BC patients undergoing NAC followed by breast and axillary surgery were enrolled in a multicentric study from 11 Breast Units.
Background: Gene expression profiling (GEP)-based prognostic signatures are being rapidly integrated into clinical decision making for systemic management of breast cancer patients. However, GEP remains relatively underdeveloped for locoregional risk assessment. Yet, locoregional recurrence (LRR), especially early after surgery, is associated with poor survival.
View Article and Find Full Text PDF